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Most pathological processes involve complex molecular pathways that can only be 
modified or blocked by a combination of medications. Combination therapy has 
become a common practice in medicine. In ophthalmology, this approach has been 
used effectively to treat bacterial, fungal, proliferative/neoplastic, and inflammatory 
eye diseases and vascular proliferation. Combination therapy also encompasses the 
synergistic effect of electromagnetic radiation and medications. However, combination 
therapy can augment inherent complications of individual interventions, therefore 
vigilance is required. Complications of combination therapy include potential 
incompatibility among compounds and tissue toxicity. Understanding these effects 
will assist the ophthalmologist in his decision to maximize the benefits of combination 
therapy while avoiding an unfavorable outcome.  
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INTRODUCTION
Combining means and therapeutics to address 
various pathologic processes is now a familiar 
topic across many, if not all, medical specialties. 
There is compelling clinical, technological and 
commercial justification for combining therapies 
into fixed and/or unfixed drug combinations or 
combining a device and a drug to achieve better 
outcomes. Usually, fixed drug combinations 
are formulated to address patient compliance 
and convenience or manufacturing costs. Other 
fixed therapies encompass the combination and 
engineering of drug and device into one unit 
as a means of drug delivery or combining a 
drug and a physical source of energy (thermal 
or certain wavelengths) to achieve a localized 
therapeutic effect. Examples are cardiovascular 
drug eluting stents1, intravitreal drug implants2, 
diabetes products, iontophoretic transdermal 
patches3, and photodynamic therapy. Such drug 
and device combinations are mainly aimed at 
realizing considerable therapeutic advantages 
as compared to administering a single drug, or 
the drug and the device separately. 
There are also convincing medical and 
biological reasons to combine two or more drugs. 
Different pathologies develop and progress 
through multiple molecular pathways and 
therefore, different mechanisms of action and 
opportunities exist to interfere and partially 
block such pathways. Capitalizing on such 
opportunities must be done with extreme 
care, since combining chemical entities and 
formulations can be toxic to specific cells, 
and sometimes to whole organs. Although Combination Therapy; Peyman and Hosseini
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such combinations may result in additive or 
synergistic therapeutic actions, they may also 
cause unfavorable outcomes; therefore stringent 
pharmacovigilance at all times is warranted. 
Awareness of the potential hazards of 
combination products has prompted many 
regulatory bodies such as the US Food and Drug 
Administration (FDA), European Medicines 
Agency (EMA), and the Japan Health Agency 
to mandate thorough screening of potential 
benefits and adverse effects. These measures 
have resulted in new guidelines and policies for 
fixed therapeutic products.4 However, there is 
considerably less control and vigilance present/
possible at the level of the practicing clinician 
for unfixed combinations (administering two or 
more drugs at variable doses and frequencies). 
There are hazards, and therefore physicians 
need to be aware of the potential risks and 
continue to share their findings with the medical 
community.  
Discussing the broad ramifications of all 
combination products would go beyond the 
scope of this paper. Therefore, we focus on 
combination drugs in ophthalmology and in 
particular, on intravitreal drug combinations. 
The eye is a unique structure, in which 
different tissues (nerve, muscle, connective 
tissue, aqueous and vitreous humor, etc.) 
interact and fuse in a compact space with well-
defined boundaries. The eye is susceptible to 
pathologies that can affect individual tissues. 
Pathological processes may also affect more 
than one tissue at a time and therefore, 
multiple drugs could be used to address each 
layer and tissue accordingly. Our current 
knowledge of many ophthalmic diseases is 
still incomplete regarding the exact causative 
molecular pathways. Current clinical practice 
categorizes a collection of disorders under 
single disease entities, e.g., glaucoma, dry eye, 
age-related macular degeneration. However, in 
the abovementioned pathologies, varying stages 
and severities of disease manifestations are the 
result of a collection of molecular pathways 
brought about by multi-factorial conditions. As 
our basic knowledge of these conditions grows, 
so do our therapeutic strategies to address 
them. Precise mapping of different molecular 
pathways allows us to devise approaches for 
each independent pathway. It is no surprise 
that no single drug can address all pathways. 
Therefore, combination approaches have become 
inevitable, and understanding the chemical 
and physical interactions of the components 
remains of paramount importance. Disregarding 
such considerations may result in irreversible 
consequences. 
Combination of drug and device within 
ophthalmology dates back to the 1970s when the 
first drug and device combination was approved 
in the USA. Ocusert (Alza Corporation, Palo 
Alto, CA, USA) was a pilocarpine-containing, 
polymer-membrane unit that provided a 
depot in the conjunctival cul-de-sac to address 
glaucoma.5 Since then, other ocular drug/
device implants such as Vitrasert and Retisert 
(Bausch & Lomb Inc., Rochester, NY, USA), both 
intravitreal devices, have been embraced in 
clinical practice. There is even an encapsulated 
cell delivery device (Neurotech USA Inc., 
Lincoln, RI, USA) in clinical development 
as an intravitreal implant which produces 
ciliary neurotrophic factor (CNTF), which can 
potentially provide benefit for patients with 
different retinal degenerative disorders.6 This 
device consists of living cells encapsulated 
within semi-permeable polymer membranes and 
supportive matrices. Recently, a new product 
was approved in the US that involves a drug 
and device combination (Ozurdex; Allergan 
Inc., Irvine, CA, USA) where the device 
injects a biodegradable dexamethasone depot 
intravitreally using a specialized disposable 
syringe and needle system.7
Peyman and colleagues8 have recently 
invented a drug and device combination 
where the device can inject a depot drug using 
jet propulsion force without needle entrance 
into the vitreous cavity, therefore, drastically 
reducing the chance of endophthalmitis.
There are other drug and device combinations 
in late-stage clinical development. Examples 
include contact lenses with drug coatings as drug 
delivery means for seasonal allergies and other 
anterior segment pathologies9,10, intraocular 
lenses with drug coatings as prophylaxis 
for post-cataract surgery, and drug coated Combination Therapy; Peyman and Hosseini
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punctal plugs to address compliance issues 
in glaucoma patients.11 Furthermore, there 
have been experiments with biodegradable 
punctal plugs to investigate antibiotic and 
steroid delivery potentials.12 Another form of 
drug device combination in ophthalmology 
is photodynamic therapy, where intravenous 
circulating drugs combined with focused 
irradiation of a certain wavelength of light 
results in activation of free radicals from that 
drug, enhancing a local coagulating effect on 
intruding choroidal/retinal vessels.13 
COMBINATIONS OF TWO OR MORE 
DRUGS
The combination of multiple chemical agents 
for ocular disorders provides an effective 
strategy to address clinical needs in acute and 
chronic conditions. When two or more different 
drugs are mixed in vitro or in vivo, they may 
interact. Some drugs change the way others 
are transported or absorbed in the tissue. Such 
interactions may occur during chemical and 
physical intraocular mixing or at the time of 
mixture of injections.
Drug interactions may increase or decrease 
drug effects. Competitive effects occur during 
combination of drugs which can be positive 
or negative, depending on whether the drugs 
have synergistic or antagonistic effects. Drug 
displacement interactions are a possibility; 
this can occur at binding or receptor sites. 
Alternatively, the combination of drugs can 
produce a new effect that neither drug produces 
on its own. The effect of combining drugs within 
an organ such as the eye can be considered 
localized. However, one needs to be alert 
towards the possible additional interactions with 
systemically dosed agents and thus, adverse 
interactions elsewhere in the body.
Ophthalmology is a specialty that is quite 
familiar with combinations of different drugs 
and therapies. As an example, endophthalmitis 
is a well known (and dreaded) condition that is 
currently addressed with unfixed combination 
therapy; at least two different classes of 
antibiotics are co-administered to provide 
coverage for both gram-negative and gram-
positive bacteria.14 Another example includes 
artificial tears and cyclosporine formulations 
(Restasis; Allergan Inc., Irvine, CA, USA), 
which are increasingly being combined to treat 
a plethora of dry eye cases. Also, different 
classes of glaucoma drugs are being prescribed 
either in fixed combinations or unfixed and 
co-prescribed combinations by physicians 
to control intraocular pressure in glaucoma 
patients. Examples of fixed combinations 
for glaucoma include brinzolamide 1% plus 
timolol 0.5% ophthalmic suspension (Azarga; 
Alcon Laboratories Inc., Fort Worth, TX, USA), 
travoprost 0.004% plus timolol 0.5% (DuoTrav; 
Alcon Laboratories Inc., Fort Worth, TX, USA), 
a fixed combination of 0.005% latanoprost and 
0.5% timolol (Xalacom; Pharmacia, Kalamazoo, 
MI, and Pfizer, New York, NY, USA), and a fixed 
combination of bimatoprost 0.03% plus timolol 
0.5% (Ganfort, Allergan, Irvine, CA, USA). 
There are also a number of fixed ophthalmic 
combinations of corticosteroids and antibiotics. 
Well known examples include Tobradex 
(dexamethasone 1 mg/ml plus tobramycin 
3 mg/ml; Alcon Laboratories Inc., Fort Worth, 
TX, USA), Zylet (loteprednol and tobramycin; 
Bausch & Lomb Inc., Rochester, NY, USA), and 
dexamethasone-netilmicin (dexamethasone 
1 mg/ml plus netilmicin 3 mg/ml). There is 
also a fixed combination of dexamethasone 0.1% 
and a macrolide (azithromycin 1%) in Durasite 
(a polycarbophil-based ophthalmic delivery 
system) in late stage clinical development 
(ISV-502, InSite Vision, Alameda, CA, USA).
Next, we will briefly discuss possible 
physical-chemical interactions between 
various drugs and comment on their possible 
applications and/or outcomes for intravitreal 
combination therapies. 
It remains almost impossible to predict 
drug interactions in different locations of an 
organ or the whole body, as transport and 
elimination routes and dynamics can vary 
greatly depending on ongoing physiological 
and pathological processes. However, there are 
a few exceptions. One of them is the vitreous 
body, where locally administered drugs can 
achieve high concentrations, at least for a 
certain period of time. It should be noted that Combination Therapy; Peyman and Hosseini
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the duration of this effect depends on the drug’s 
half-life, molecular weight, molecular size, 
electric charge, elimination route, etc.
Peyman  and  colleagues 15  used  the 
combination of steroids and antibiotics in the 
vitreous body for the first time in 1974 to treat 
bacterial endophthalmitis. This combination 
approach followed their findings regarding 
diffusion processes governing the transport of 
peroxidase as a trace material in the posterior 
segment. They discovered that junctional 
complexes of the retinal pigment epithelium 
act as the limiting barrier of transport in both 
directions.16 This prompted them to conclude 
that intravitreal injections could be feasible to 
achieve high concentrations of certain drugs 
in the vitreous space and therefore, anticipate 
a local biological effect to address ocular 
pathologies.
Specific physiochemical reactions for a drug 
or combination of drugs must be considered 
when one administers medications intravitreally. 
Another major consideration is related to the 
biological effect that a drug or the combination 
of multiple drugs can induce in ocular tissues. 
Such a biological effect may be the result of 
tissue reactions to each individual drug or the 
products of their combination.
The physiochemical adverse reactions of a 
single, “approved” drug are usually mapped 
out and generally deemed safe to apply due to 
extensive preclinical and clinical testing that 
is undertaken prior to approval. Nevertheless, 
vigilance is still required when a single drug is 
being used “off-label” for a different indication. 
The challenge becomes even greater when two or 
more drugs are combined and their combination 
may cause new physiochemical reactions within 
the mixture in vitro or within the organ. Such 
adverse effects may manifest as incompatibility, 
which is described as preventable or reversible 
precipitation or insolubility and recognizable as 
crystals, turbidity, or haziness. Incompatibility 
can be easily caused by acid-base reactions. 
However, other scenarios are also possible, 
such as non-dissociated salts of organic ions, 
salting out, salts of inorganic divalent ions, 
desolvation of non-ionized organic drugs, and 
organic ion-inorganic ion salts.17 
Another possible physiochemical reaction 
due to combinations of drugs stems from 
instability, which can result from hydrolysis 
and oxidation. The combination of chemical 
entities can cause degradation products and 
such products are often unstable chemicals that 
may be less active or inactive therapeutically, 
but more importantly, they can become toxic 
products which are not always visually 
discernable.18 Degradation can be caused either 
chemically (by factors such as concentration 
dependence, solution pH, photochemical, 
or insoluble salts) and/or physically (e.g., 
adsorption which is the loss of drug via adhesion 
to solid surfaces, complexation of ions such 
as calcium with tetracycline, or salting out by 
strong electrolytes).
As mentioned, resultant physiochemical 
drug interactions can become toxic and therefore, 
when contemplating new medications for 
intraocular administration, care should be given 
to such adverse side effects. Different cell layers 
of the retina, the endothelium of the cornea, 
and the crystalline lens are among the ocular 
tissues that have been reported to be subject 
to toxicity as a result of drug degradation or 
complexation products. One example of such 
an adverse effect was reported during cataract 
surgery while mixing chondroitin sulfate 
with hyaluronate sodium (Viscoat; Alcon 
Laboratories Inc., Fort Worth, TX, USA).19 The 
high concentration of phosphate in Viscoat 
apparently combined with calcium from the 
intracameral irrigating solution, resulting in 
clinically visible precipitation. There are also 
reports on clinically significant crystalline 
deposits on intraocular lenses with the use 
of Healon GV (a high concentration, high 
molecular-weight sodium hyaluronate).20 It 
seems that phosphate components used to buffer 
the viscoelastic agents precipitates with calcium 
from the irrigating solution. Another group 
reported precipitation of tissue plasminogen 
activator as a result of salt formation due to 
calcium and magnesium in the balanced salt 
solution (BSS) reacting with phosphate anions.21
The neutrality of pH for medical formulations 
while desirable, is a hard target to achieve 
for many compounds. Many formulations Combination Therapy; Peyman and Hosseini
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become unstable and suffer from lack of 
(partial) solubility if pushed toward a fixed 
pH. Ciprofloxacin is a fair example that can 
be stable and soluble at a pH around 4.5, but 
would start precipitating if pH is altered to 7.0.
Episodes of white precipitation on the 
corneal surface were reported among more 
than 600 patients with bacterial keratitis, 
treated with topical ciprofloxacin 0.3%.22 The 
adverse effect became more alarming when 
it was concluded that this precipitate was 
delaying re-epithelialization by as much as 
55%. Ciprofloxacin was the focus of another 
study where precipitation was reported in 
the vitreous (regardless of the presence of 
vancomycin) at body temperature. However 
the amount of active drug after precipitation 
still remained above the MIC90 (minimum 
inhibitory concentration required to inhibit 
the growth of 90% of organisms) for most 
gram-negative microorganisms such that the 
antimicrobial effect remained intact.23
All of the above-mentioned examples 
were related to clinically visible precipitation, 
however,  microprecipitation  and/or 
incompatibility may also occur. A combination 
of vancomycin and ceftazidime has been 
routinely injected intravitreally for suspected 
bacterial endophthalmitis. There are claims of 
precipitation when these two antibiotics are 
physically mixed. Also, some investigators 
have reported pH-dependent precipitation 
of vancomycin regardless of the presence of 
ceftazidime in the medium.24 
As the number of intraocular injectable 
candidates increases, more investigations 
are necessary to study such physiochemical 
interactions. However, designing such 
studies under conditions that would mimic 
the physiological environment of ocular 
tissues remains challenging. A cornerstone of 
maintaining such an environment is preservation 
of a constant internal environment in terms of 
temperature, fluid volume, and fluid consistency, 
collectively called homeostasis. One important 
factor in homeostasis is the maintenance of a 
relatively constant pH. Many buffering systems 
are employed in the body to support pH levels. 
Examples are bicarbonate in the interstitial 
fluid, phosphates, and proteins, which are also 
present intracellularly. An important source 
of H+ in the body is cellular metabolism as a 
result of oxidation of glucose and fatty acids. 
These hydrogen atoms are the most reactive 
cations in the body and they become crucial 
when one considers the functional groups of 
proteins, which are negatively charged and 
can react with them. Such reactions may cause 
alterations in the structural conformation of 
the protein and consequently its behavior. 
Many new drugs in development are protein-
based and therefore such possible reactions 
with other drugs become noteworthy. Less 
is known about the buffering capacity of the 
vitreous in general, until recently.25 A series 
of experiments involving the addition of 
triamcinolone acetonide, sodium hydroxide, 
and hydrochloride acids, were designed to 
investigate the buffering ability of this ocular 
medium. In this investigation, the bovine 
vitreous showed superior buffering aptitude 
against the addition of acids and bases, when 
compared to a control medium such as normal 
saline. This superiority was as much as five 
times more than that of normal saline, meaning 
most intravitreal injectable drugs can easily be 
buffered by an intact vitreous. 
It has been demonstrated that intraocular 
injections of drugs can cause toxicity to different 
tissues. Such toxicity is usually shown by 
means of postmortem histologic studies in 
animal models. Toxicity to retinal cell layers 
can be shown in vivo using electroretinography. 
Toxicity in the anterior segment such as lens 
opacification can easily be revealed with slit-
lamp biomicroscopy. Corneal toxicity usually 
manifests as endothelial cell dysfunction which 
can be shown using a corneal stress test.26 
Less risky methods for testing the biological 
effects of combination (and single) drugs in 
preclinical settings include bacteria, specialized 
cell cultures, ocular inflammatory receptors, 
viruses, and proliferative tissues. 
Currently,  therapy  for  bacterial 
endophthalmitis consists of combination 
therapy, a mixture of antibiotics aimed at 
addressing both gram-negative and gram-
positive bacteria. This is the standard of Combination Therapy; Peyman and Hosseini
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care since such a sight-threatening condition 
allows no time to explore the nature of the 
causative organism. Antibiotics usually 
interfere with bacterial cell wall or ribosomal 
protein synthesis. Gram-positive bacteria 
have different cell walls from gram-negative 
microorganisms and therefore a single antibiotic 
may be ineffective on the wrong target. The 
current antibiotic treatment for acute-onset 
bacterial endophthalmitis includes a mixture 
of vancomycin for gram-positive coverage 
and either ceftazidime or an aminoglycoside 
for gram-negative coverage. Aminoglycosides 
do not interact with the cell wall but inhibit 
protein synthesis by binding to the 30S bacterial 
ribosomal subunit, resulting in misreading of 
the messenger RNA. Toxicity levels for each 
of these antibiotics have been determined and 
they are generally considered to be safe for 
administration through the pars plana.27-37 
When  Peyman  and  colleagues  first 
introduced combination therapy for posterior 
segment disorders15,27-29,38, their goal was to 
directly combat the microorganisms and at 
the same time reduce ongoing inflammation 
associated with the process. Of note, bacterial 
infection in the ocular media is accompanied 
by considerable intraocular inflammation. 
Examples of inflammatory mediators include 
lipoxygenases, which produce leukotrienes, and 
cyclooxygenases, which produce prostaglandins 
and thromboxanes. Lipoxygenases are mainly 
inhibited by steroids, whereas cyclooxygenases 
are inhibited by non-steroidal anti-inflammatory 
compounds (NSAIDs). 
Combinations of steroids and amphotericin 
B have been investigated for fungal infections 
which are also typically accompanied by 
marked inflammation.39 Results have shown that 
significant reduction in intraocular inflammation 
can be achieved with combination therapy in 
comparison to single agents or no treatment.40,41 
In current practice, corticosteroids 
are important candidates for intravitreal 
applications. Non-toxic doses of dexamethasone 
for ocular tissues are close to 400 μg40. Currently, 
dexamethasone is routinely administered at a 
dose of 400 μg, which is markedly lower than the 
subconjunctival dose at 2 to 5 mg, or systemic 
dose at 75 mg. However, dexamethasone 
phosphate is a water soluble salt that can be 
eliminated from the vitreous cavity within a few 
days. It thus has a half-life of approximately 3 
hours (the biological half-life is more than 40 
hours). Recent intravitreal and subconjunctival 
pharmacokinetic studies mapped this fast 
elimination in a rabbit study  in vivo.42 
Triamcinolone acetonide, which has a half-life 
of 18.6 days, is now the candidate of choice to 
sustain longer residence in ocular tissue. The 
usual dose for intravitreal administration is 
2 to 4 mg, although higher doses have also 
been explored with success.41,43-48 Due to the 
long acting nature of triamcinolone, it is an 
acceptable choice for treatment of conditions 
such as cystoid macular edema (CME) and 
many other persistent posterior segment 
inflammatory conditions. One major reservation 
for intraocular application of steroids relates to 
their side effects including cataract formation 
and elevation of intraocular pressure.49 
A triple combination of clindamycin, 
aminoglycosides, and dexamethasone in the 
infusion fluid has been investigated by our 
group since 1990 for prophylaxis of bacterial 
infection in vitrectomy procedures.50 
COMBINATIONS OF DRUG AND DEVICE
A combination therapy, per regulatory 
guidelines, can include a device and a drug. 
Steroids have been successfully formulated 
and incorporated into implantable devices. 
Retisert is an example of a drug and device 
combination, engineered as a non-biodegradable 
intravitreal implant for slow but steady release 
of fluocinolone acentonide for up to 3 years. The 
device is sutured into the vitreous cavity, away 
from the optical axis and acts as a steady drug 
delivery system.49 The high incidence of cataract 
formation and intraocular pressure elevation in 
patients receiving this implant were among the 
reasons for its lack of endorsement by leading 
ophthalmologists. In 2010, the FDA approved 
Ozurdex, which is a dexamethasone intravitreal 
implant for treatment of adults with macular 
edema following branch retinal vein occlusion 
(BRVO) or central retinal vein occlusion (CRVO). Combination Therapy; Peyman and Hosseini
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Ophthalmologists use this implant for uveitis 
and other non-infectious inflammations of the 
posterior segment. This is an example of a 
specialized drug depot combined with a device 
that injects a biodegradable amount of a special 
dexamethasone formulation for slow and steady 
release.51 Its approval was based on data from a 
26-week multicenter double-blind randomized 
clinical study in which 77 patients received 
Ozurdex 0.7 mg while 76 patients received 
sham injections. Although such a novel drug 
delivery platform is exciting from a scientific 
point of view, critics may question the real 
world utility of a steroid depot formulation 
as the ideal treatment for such indications. 
Over the past several years, clinicians have 
used intraocular injections of triamcinolone 
acetonide (Kenalog) off-label for the treatment 
of macular edema due to BRVO and CRVO.   
Ozurdex is designed for a sustained release 
of dexamethasone but at a much higher price 
compared to triamcinolone acetonide.
Another interesting vehicle for delivery 
of steroids is iontophoresis technology. 
Iontophoresis utilizes an electric current to 
drive charged ions (drugs) across a barrier 
such as the sclera or the cornea. Eyegate 
Pharmaceuticals has recently completed a 
phase II study on management of anterior 
uveitis using an iontophoretic drug delivery 
system for ocular application.52 The safety, 
tolerability, and efficacy of four iontophoretic 
doses of dexamethasone phosphate ophthalmic 
solution were investigated in patients with 
non-infectious anterior segment uveitis. The 
technology, however, has certain limitations; 
for example, the number of charges on a given 
drug ion partially determines its mobility. 
Also, the drug’s molecular size will affect its 
transport kinetics and other competing ions 
in the formulation or tissue could adversely 
affect the delivery profile.
Other delivery devices are in development 
to address on-target transport challenges that 
new drugs and therapies face to reach the 
posterior segment. A novel injection device 
for intravitreal and subconjunctival drug 
delivery has been developed by Peyman and 
co-workers53. The device utilizes a micro-
needle to “hook” onto the ocular surface; the 
injection of medication into the vitreous cavity 
is achieved by propelling the formulation using 
the jet force produced by device internals. The 
device has a number of advantages: the actual 
injection time is a fraction of a second while 
the whole procedure takes a few seconds; the 
pars plana is predetermined by placing the 
tip of the probe adjacent to the limbus; and 
the procedure can potentially be executed 
by a general ophthalmologist. Furthermore, 
there is no needle penetration into the vitreous 
cavity, which eliminates the danger of abrupt 
eye movement during the injection phase. This 
should also theoretically lower the chances of 
microflora transfer from the ocular surface into 
the eye, minimizing the risk of endophthalmitis. 
Additionally, preclinical studies suggest that 
there is no drug regurgitation, which frequently 
occurs after intravitreal and subconjunctival 
injections (unpublished data). 
Viral infections of the posterior segment 
have also been targeted with combination 
therapies. Viral infections develop in different 
stages and most antiviral drugs interfere with 
the replication stage. They do so by integrating 
defective nucleoside analogues into the viral 
genome and thus, targeting specific viral 
enzymes or proteins. Fortunately the incidence 
of cytomegalovirus retinopathy is decreasing 
thanks in part to the employment of advanced 
therapies for HIV infected individuals. 
Nevertheless, antiviral therapies for this 
condition are still being used, and a drug and 
device combination (Vitrasert) for intravitreal 
implantation is available for slow release of 
ganciclovir up to 8 months. This implant was 
developed before Retisert and its implantation 
procedure resembles that of Retisert. Antiviral 
drugs were injected intravitreally before the 
introduction of implants. Different doses 
were used to administer each compound, for 
example, ganciclovir at 2000 μg, foscarnet at 
1000 to 2000 μg, and acyclovir at 240 μg. Other 
antiviral drugs such as trifluorothymidine and 
vidarabine have also been injected intravitreally. 
A combination of ganciclovir and foscarnet 
(or other antiviral drugs) can also be used for 
mixed therapy.Combination Therapy; Peyman and Hosseini
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IMPLICATIONS OF COMBINATION 
THERAPY
Several ocular pathologies could benefit 
from combination therapies. Diseases such 
as proliferative vitreoretinopathy (PVR), 
vascular proliferation in age-related macular 
degeneration (AMD), diabetic retinopathy, and 
malignant tumors, exhibit distinctly different 
stages which can be potential targets for 
different anti-proliferative, anti-inflammatory, 
and matrix metalloproteinase inhibiting agents. 
Current management of vascular proliferation 
has been dominated by blocking the activity 
of existing vascular endothelial growth factor 
(VEGF), while other small and large molecular 
candidates are being investigated to block the 
production of VEGF. Targeting VEGF in AMD 
has probably provided the biggest advance for 
this ever-growing condition. Currently, the 
two prominent treatment options for VEGF 
blockage include intravitreal administration of 
ranibizumab (Lucentis) or the off-label use of 
bevacizumab (Avastin). However, other VEGF 
blocking treatments are in development and 
probably the closest compound to approval 
is aflibercept (VEGF Trap), developed by 
Regeneron Pharmaceuticals. Aflibercept is a 
fusion protein specifically designed to bind all 
forms of vascular endothelial growth factor-A 
(called VEGF-A). 
A  number  of  candidates  for  co-
administration with VEGF blocking agents 
are being investigated clinically and results 
thus far are promising. These include not only 
intravitreal combinations of drug candidates 
but also intravitreal and topical combinations 
aimed at increasing efficacy and/or decreasing 
injection frequency and cost, thus ultimately 
improving compliance. In one clinical study, 
the combination of topical bromfenac 0.09% 
(Xibrom, Ista Pharmaceuticals Inc., Irvine, CA, 
USA), which is an NSAID, and the intravitreal 
injection of ranibizumab resulted in a three-
fold decrease in the frequency of injections.54 
Another study could not replicate these results 
but the authors pointed out that their follow-
up period was only 2 months, as opposed 
to 6 months in the original study.55 Another 
NSAID, which was recently combined in a 
clinical setting with intravitreal injections of 
anti-VEGF compounds, is nepafenac (Nevanac) 
for treatment of recalcitrant exudative macular 
degeneration. Based on a 3 month study, the 
authors reported no significant change in 
visual acuity or quantitative optical coherence 
tomography (OCT) measurements but noted a 
trend toward improved anatomy and qualitative 
OCT findings when topical nepafenac was added 
to monthly anti-VEGF injections in patients 
with persistent intraretinal cysts, subretinal 
fluid, and pigment epithelial detachment.56
Other therapies that can be combined with 
anti-VEGF therapy include photodynamic 
therapy (PDT), transpupillary thermotherapy 
(TTT), and intravitreal steroid injections. There 
have been a number of uncontrolled clinical 
studies where combinations of VEGF therapy 
with steroids and PDT (as a combo or triple 
treatment) were investigated, with favorable 
results. Triple therapy for posterior segment 
diseases such as wet type AMD has been 
investigated by a number of clinicians.57-59 It 
involves a treatment protocol with intravitreal 
injections of a steroid such as dexamethasone 
or triamcinolone, and an anti-VEGF compound 
such as pegaptanib (Macugen), bevacizumab, 
or ranibizumab, followed by short-duration 
photodynamic therapy that can stabilize vision 
and reduce the burden of frequent injections. 
However, it is still unclear which VEGF forms 
should be blocked for each disease and to what 
extent should such blockade be pursued, since 
VEGF also has physiologic roles for many 
processes in the body, such as wound healing, 
survival, and regeneration of healthy cells.
CONCLUSION
Combination therapies are increasingly 
expanding due to the growth of knowledge 
about the core pathologic mechanisms of 
diseases. Ophthalmology has been an area 
of successful implementation of a number of 
fixed and unfixed drug combinations, along 
with drug/device combinations. Investigators 
have combined different drugs with devices to 
address challenging needs of chronic conditions Combination Therapy; Peyman and Hosseini
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and drug delivery problems. Such combination 
approaches should ideally achieve clear 
advantages in terms of therapeutic efficacy, 
lowered toxicity, and increased compliance. 
There are also risks that need to be mitigated, 
if possible. Combinations of pharmaceutical 
compounds may precipitate adverse physical 
and chemical interactions, both in vitro during 
mixing and in vivo upon delivery. Although 
research on adverse effects of drug/drug 
and drug/device interactions is regulated for 
commercial combinations, there is little control 
over off-label and unfixed combinations devised 
and utilized by clinicians. More research is 
warranted on new combination therapies to 
increase efficacy and safety.
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